Ira M. Jacobson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ira M. Jacobson has a total of 279 co-authors. Here are the top co-authors by number of shared publications:
- Eric Lawitz
Texas Liver Institute, University of Texas Health San Antonio, San Antonio, Texas, USA
4 shared publications - Robert G. Gish
Hepatitis B Foundation, Doylestown, USA
4 shared publications - Heiner Wedemeyer
Department of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hannover Medical School, Hannover, Germany
3 shared publications - Paul Martin
University of Miami Miller School of Medicine, Miami, USA
3 shared publications - Calvin Q. Pan
Division of Gastroenterology and Hepatology, Department of Medicine, NYU Langone Health New York University Grossman School of Medicine New York USA
2 shared publications - Christopher L. Bowlus
Division of Gastroenterology and Hepatology University of California Davis School of Medicine Sacramento California USA
2 shared publications
Latest Publications
- Open Access
- 12 August 2026
- Published by Wolters Kluwer Health in Hepatology
A First-in-Human study of AHB-137, an unconjugated antisense oligonucleotide, in healthy subjects and patients with chronic hepatitis B
Background and Aims: AHB-137 is a novel ASO targeting a conserved region near the 3′ end of all HBV mRNA. This first-in-human phase 1 study evaluated the safety, tolerability, pharmacokinetics (PK), and antiviral efficacy in healthy subjects and chronic hepatitis B (CHB) patients. Approach and Results: Forty healthy subjects were randomized into 4 placebo-controlled single ascending dose (100–450 mg, 6:2 AHB-137:placebo) cohorts and one multiple-dose (MD; 300 mg, 6:2) cohort receiving 4 weekly subcutaneous doses with a day 4 loading dose (5 doses). Twenty-four virally suppressed, HBeAg-negative CHB patients on stable nucleos(t)ide analog therapy were enrolled: 4 in an open-label 300-mg MD cohort (5 doses) and 20 in 2 placebo-controlled 300-mg MD cohorts (4:1, stratified by baseline HBsAg), receiving an additional loading dose on day 11 (6 doses). Treatment-related adverse events occurred in 73% of healthy subjects and 71% of CHB patients and were primarily mild or moderate injection-site reactions and headaches. No treatment-related serious adverse events, discontinuations, or deaths were observed. PK profiles showed rapid absorption ( T max 2.96–5.50 h), dose-proportional exposure, no significant accumulation, long terminal half-life (150–220 h), and minimal renal excretion. In CHB patients, AHB-137 treatment led to a rapid HBsAg decline (mean 0.7–1.0 log 10 IU/mL). HBsAg loss (<0.05 IU/mL) for at least one time point was observed in 3 patients, including 2 with baseline HBsAg <1 IU/mL and 1 with baseline HBsAg <1.5 IU/mL. Conclusions: In this phase 1 study, AHB-137 demonstrated an acceptable safety profile, predictable PK, and rapid and prolonged HBsAg reductions, supporting further evaluation of dosing and treatment duration in CHB.
- 12 August 2026
- Published by Wolters Kluwer Health in Hepatology
Open AccessA First-in-Human study of AHB-137, an unconjugated antisense oligonucleotide, in healthy subjects and patients with chronic hepatitis B
Background and Aims: AHB-137 is a novel ASO targeting a conserved region near the 3′ end of all HBV mRNA. This first-in-human phase 1 study evaluated the safety, tolerability, pharmacokinetics (PK), and antiviral efficacy in healthy subjects and chronic hepatitis B (CHB) patients. Approach and Results: Forty healthy subjects were randomized into 4 placebo-controlled single ascending dose (100–450 mg, 6:2 AHB-137:placebo) cohorts and one multiple-dose (MD; 300 mg, 6:2) cohort receiving 4 weekly subcutaneous doses with a day 4 loading dose (5 doses). Twenty-four virally suppressed, HBeAg-negative CHB patients on stable nucleos(t)ide analog therapy were enrolled: 4 in an open-label 300-mg MD cohort (5 doses) and 20 in 2 placebo-controlled 300-mg MD cohorts (4:1, stratified by baseline HBsAg), receiving an additional loading dose on day 11 (6 doses). Treatment-related adverse events occurred in 73% of healthy subjects and 71% of CHB patients and were primarily mild or moderate injection-site reactions and headaches. No treatment-related serious adverse events, discontinuations, or deaths were observed. PK profiles showed rapid absorption ( T max 2.96–5.50 h), dose-proportional exposure, no significant accumulation, long terminal half-life (150–220 h), and minimal renal excretion. In CHB patients, AHB-137 treatment led to a rapid HBsAg decline (mean 0.7–1.0 log 10 IU/mL). HBsAg loss (<0.05 IU/mL) for at least one time point was observed in 3 patients, including 2 with baseline HBsAg <1 IU/mL and 1 with baseline HBsAg <1.5 IU/mL. Conclusions: In this phase 1 study, AHB-137 demonstrated an acceptable safety profile, predictable PK, and rapid and prolonged HBsAg reductions, supporting further evaluation of dosing and treatment duration in CHB.
- Open Access
- 13 April 2026
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 10 (5)
Seladelpar in patients with primary biliary cholangitis and compensated cirrhosis: Efficacy and safety from RESPONSE and ASSURE studies
Background: Treatment options are limited for patients with primary biliary cholangitis (PBC) and cirrhosis. Seladelpar, a first-in-class delpar (selective PPAR-δ agonist), had generally similar efficacy and safety among patients with versus without compensated cirrhosis in the phase 3 RESPONSE study. Here we provide additional data on seladelpar in patients with compensated cirrhosis from the phase 3 program. Methods: In RESPONSE, patients with PBC and an inadequate response or intolerance to UDCA were randomized 2:1 to seladelpar 10 mg or placebo for 1 year. Upon completion, patients rolled over into the open-label (seladelpar 10 mg) phase 3 ASSURE study, which also enrolled patients from earlier seladelpar legacy PBC studies. Here, we assessed the composite endpoint [alkaline phosphatase (ALP) <1.67×upper limit of normal (ULN), ALP decrease ≥15%, and total bilirubin ≤ULN], other laboratory changes, and safety in all patients with cirrhosis from RESPONSE and an interim analysis of the ongoing ASSURE study through January 2024. Results: Twenty-seven patients with compensated cirrhosis enrolled in RESPONSE (18 seladelpar, 9 placebo). At month 12, 38.9% and 22.2% of patients in the seladelpar and placebo groups, respectively, met the composite endpoint; mean percent change from baseline in ALP was −37.1% and −10.1%, respectively. Upon rollover to ASSURE (13 seladelpar, 6 placebo), ALP declines were maintained for up to 18 months. An additional 35 patients with compensated cirrhosis in ASSURE from legacy studies had similar reductions in ALP with up to 2 years of treatment. Bilirubin remained overall stable. No treatment-related serious adverse events occurred. Variceal bleeding and/or ascites developed in 3 patients after ≥9 months. Conclusions: Seladelpar decreased markers of cholestasis and was overall safe and well-tolerated in patients with PBC and compensated cirrhosis.
- 13 April 2026
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 10 (5)
Open AccessSeladelpar in patients with primary biliary cholangitis and compensated cirrhosis: Efficacy and safety from RESPONSE and ASSURE studies
Background: Treatment options are limited for patients with primary biliary cholangitis (PBC) and cirrhosis. Seladelpar, a first-in-class delpar (selective PPAR-δ agonist), had generally similar efficacy and safety among patients with versus without compensated cirrhosis in the phase 3 RESPONSE study. Here we provide additional data on seladelpar in patients with compensated cirrhosis from the phase 3 program. Methods: In RESPONSE, patients with PBC and an inadequate response or intolerance to UDCA were randomized 2:1 to seladelpar 10 mg or placebo for 1 year. Upon completion, patients rolled over into the open-label (seladelpar 10 mg) phase 3 ASSURE study, which also enrolled patients from earlier seladelpar legacy PBC studies. Here, we assessed the composite endpoint [alkaline phosphatase (ALP) <1.67×upper limit of normal (ULN), ALP decrease ≥15%, and total bilirubin ≤ULN], other laboratory changes, and safety in all patients with cirrhosis from RESPONSE and an interim analysis of the ongoing ASSURE study through January 2024. Results: Twenty-seven patients with compensated cirrhosis enrolled in RESPONSE (18 seladelpar, 9 placebo). At month 12, 38.9% and 22.2% of patients in the seladelpar and placebo groups, respectively, met the composite endpoint; mean percent change from baseline in ALP was −37.1% and −10.1%, respectively. Upon rollover to ASSURE (13 seladelpar, 6 placebo), ALP declines were maintained for up to 18 months. An additional 35 patients with compensated cirrhosis in ASSURE from legacy studies had similar reductions in ALP with up to 2 years of treatment. Bilirubin remained overall stable. No treatment-related serious adverse events occurred. Variceal bleeding and/or ascites developed in 3 patients after ≥9 months. Conclusions: Seladelpar decreased markers of cholestasis and was overall safe and well-tolerated in patients with PBC and compensated cirrhosis.
- Open Access
- 24 June 2025
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 121 (5) , 1140-1153
Long-Term Efficacy and Safety of Selective PPARδ Agonist Seladelpar in Primary Biliary Cholangitis: ASSURE Interim Study Results
INTRODUCTION: The objective of these analyses was to evaluate interim data from the ongoing, open-label, long-term efficacy and safety ASSURE study of seladelpar, a selective peroxisome proliferator-activated receptor δ agonist, in primary biliary cholangitis. METHODS: Patients rolling over from the phase 3, randomized, placebo-controlled, 12-month RESPONSE study or with previous participation in earlier legacy seladelpar studies were enrolled. Interim evaluations included composite biochemical response (alkaline phosphatase <1.67 upper limit of normal, total bilirubin ≤ upper limit of normal, and alkaline phosphatase decrease ≥15%), pruritus numerical rating scale (NRS) change among patients with a baseline score ≥4, and safety. RESULTS: At interim cutoff, 337 patients were enrolled and received ≥1 seladelpar 10 mg dose: 54 placebo-treated and 104 seladelpar-treated from RESPONSE and 179 from legacy studies. The composite response rate at RESPONSE completion was 62% (79/128) with seladelpar and 20% (13/65) with placebo. After 12 months in ASSURE, among patients who rolled over from RESPONSE, response rates were 72% (21/29) in patients continuing seladelpar and 94% (15/16) in crossover seladelpar patients. In legacy trial patients, response rates were 73% (120/164) and 70% (69/99) after 12 and 24 months of treatment in ASSURE, respectively. The NRS decrease at RESPONSE completion in seladelpar-treated patients with baseline NRS ≥4 (−3.4) was maintained after 6 additional months of treatment (−3.8); changes were similar in crossover seladelpar (−3.8) and legacy patients (−3.5) after 6 months of treatment in ASSURE. No seladelpar-related serious adverse events were reported. DISCUSSION: Seladelpar demonstrated durable improvements in cholestatic biomarkers and pruritus in patients with primary biliary cholangitis with up to 2 years of treatment and remained overall safe with long-term use. Clinicaltrials.gov: NCT03301506.
- 24 June 2025
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 121 (5) , 1140-1153
Open AccessLong-Term Efficacy and Safety of Selective PPARδ Agonist Seladelpar in Primary Biliary Cholangitis: ASSURE Interim Study Results
INTRODUCTION: The objective of these analyses was to evaluate interim data from the ongoing, open-label, long-term efficacy and safety ASSURE study of seladelpar, a selective peroxisome proliferator-activated receptor δ agonist, in primary biliary cholangitis. METHODS: Patients rolling over from the phase 3, randomized, placebo-controlled, 12-month RESPONSE study or with previous participation in earlier legacy seladelpar studies were enrolled. Interim evaluations included composite biochemical response (alkaline phosphatase <1.67 upper limit of normal, total bilirubin ≤ upper limit of normal, and alkaline phosphatase decrease ≥15%), pruritus numerical rating scale (NRS) change among patients with a baseline score ≥4, and safety. RESULTS: At interim cutoff, 337 patients were enrolled and received ≥1 seladelpar 10 mg dose: 54 placebo-treated and 104 seladelpar-treated from RESPONSE and 179 from legacy studies. The composite response rate at RESPONSE completion was 62% (79/128) with seladelpar and 20% (13/65) with placebo. After 12 months in ASSURE, among patients who rolled over from RESPONSE, response rates were 72% (21/29) in patients continuing seladelpar and 94% (15/16) in crossover seladelpar patients. In legacy trial patients, response rates were 73% (120/164) and 70% (69/99) after 12 and 24 months of treatment in ASSURE, respectively. The NRS decrease at RESPONSE completion in seladelpar-treated patients with baseline NRS ≥4 (−3.4) was maintained after 6 additional months of treatment (−3.8); changes were similar in crossover seladelpar (−3.8) and legacy patients (−3.5) after 6 months of treatment in ASSURE. No seladelpar-related serious adverse events were reported. DISCUSSION: Seladelpar demonstrated durable improvements in cholestatic biomarkers and pruritus in patients with primary biliary cholangitis with up to 2 years of treatment and remained overall safe with long-term use. Clinicaltrials.gov: NCT03301506.
- 26 May 2025
- Published by Elsevier in Clinics in Liver Disease
- Vol. 29 (3)
The Liver in Systemic Disease
- 26 May 2025
- Published by Elsevier in Clinics in Liver Disease
- Vol. 29 (3)
The Liver in Systemic Disease
- Open Access
- 1 May 2025
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 9 (5)
Awareness of metabolic dysfunction–associated steatotic liver disease (MASLD) in 4 major cities in the United States
Export
- 1 May 2025
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 9 (5)
Open AccessAwareness of metabolic dysfunction–associated steatotic liver disease (MASLD) in 4 major cities in the United States
Export
- 12 April 2024
- Published by Wiley in Journal of Viral Hepatitis
- Vol. 31 (S1) , 35-40
Monitoring for liver cancer post‐gene therapy—How much and how often?
Hepatocellular carcinoma (HCC) has long been recognized as a complication in people with chronic liver disease, particularly those with cirrhosis. Two gene therapies for haemophilia A and B recently approved in Europe and the US utilize adeno‐associated virus (AAV) vectors designed to target hepatocytes. A number of other AAV gene therapies are undergoing clinical investigation for both liver and extrahepatic diseases, many of which likely transduce hepatocytes as well. Although AAV vectors predominantly persist in episomal forms, concerns about insertional mutagenesis have arisen due to findings in pre‐clinical models and in a small subset of human HCC cases featuring wild‐type AAV integrations in proximity to potential oncogenes. Despite the absence of any causative link between AAV vector therapy and HCC in approved extrahepatic gene therapies or haemophilia gene therapy trials, the package inserts for the recently approved haemophilia gene therapies advise HCC screening in subsets of individuals with additional risk factors. In this review, we discuss HCC risk factors, compare various screening modalities, discuss optimal screening intervals, and consider when to initiate and possibly discontinue screening. At this early point in the evolution of gene therapy, we lack sufficient data to make evidence‐based recommendations on HCC screening. While AAV vectors may eventually be shown to be unassociated with risk of HCC, we presently favour a cautious approach that entails regular surveillance until such time as it is hopefully proven to be unnecessary.
- 12 April 2024
- Published by Wiley in Journal of Viral Hepatitis
- Vol. 31 (S1) , 35-40
Monitoring for liver cancer post‐gene therapy—How much and how often?
Hepatocellular carcinoma (HCC) has long been recognized as a complication in people with chronic liver disease, particularly those with cirrhosis. Two gene therapies for haemophilia A and B recently approved in Europe and the US utilize adeno‐associated virus (AAV) vectors designed to target hepatocytes. A number of other AAV gene therapies are undergoing clinical investigation for both liver and extrahepatic diseases, many of which likely transduce hepatocytes as well. Although AAV vectors predominantly persist in episomal forms, concerns about insertional mutagenesis have arisen due to findings in pre‐clinical models and in a small subset of human HCC cases featuring wild‐type AAV integrations in proximity to potential oncogenes. Despite the absence of any causative link between AAV vector therapy and HCC in approved extrahepatic gene therapies or haemophilia gene therapy trials, the package inserts for the recently approved haemophilia gene therapies advise HCC screening in subsets of individuals with additional risk factors. In this review, we discuss HCC risk factors, compare various screening modalities, discuss optimal screening intervals, and consider when to initiate and possibly discontinue screening. At this early point in the evolution of gene therapy, we lack sufficient data to make evidence‐based recommendations on HCC screening. While AAV vectors may eventually be shown to be unassociated with risk of HCC, we presently favour a cautious approach that entails regular surveillance until such time as it is hopefully proven to be unnecessary.
- Open Access
- 16 November 2023
- Published by Wolters Kluwer Health in Hepatology
- Vol. 79 (5) , 1117-1128
Prevalence and characteristics of hepatitis delta virus infection in patients with hepatitis B in the United States: An analysis of the All-Payer Claims Database
Background and Aims: Hepatitis delta virus (HDV) leads to the most severe form of viral hepatitis; however, the prevalence of HDV is not well understood. Using real-world data from the All-Payer Claims Database (APCD), this study estimates the prevalence of HBV/HDV infection among the chronic hepatitis B (HBV) population and describes patient/clinical characteristics for adults with HBV/HDV infection in the United States (US). Approach and Results: Adults (≥ 18 y) with ≥1 inpatient claim or ≥2 outpatient claims for HDV infection or HBV in the APCD from 1/1/2014 to 12/31/2020 were identified. HDV prevalence was calculated as the proportion of patients with HBV/HDV infection among total patients with HBV infection. Patient characteristics, socioeconomic status, advanced liver complications (e.g., cirrhosis, hepatocellular carcinoma), and comorbidities were assessed. A total of 6,719 -patients were diagnosed with HBV/HDV among 144,975 with HBV and 12-months of continuous data, for a prevalence of 4.6%. At diagnosis, 31.7% of patients with HBV/HDV had advanced liver complications, including compensated cirrhosis (16.3%) and decompensated cirrhosis (10.4%). Diabetes (50.5%), hypertension (49.8%), HIV infection (30.9%), were the top three comorbidities. Conclusion: In a large database capturing approximately 80% of the US insured population, HBV/HDV infection prevalence was 4.6% among HBV-infected adults. HDV-infected patients had high rates of baseline liver complications and other comorbidities at time of diagnosis, suggesting potentially delayed diagnosis and/or treatment. Earlier identification of HBV/HDV infection among the HBV population may provide opportunities to improve linkage to care and treatment, thereby reducing the risk of liver-related morbidity and mortality. Export
- 16 November 2023
- Published by Wolters Kluwer Health in Hepatology
- Vol. 79 (5) , 1117-1128
Open AccessPrevalence and characteristics of hepatitis delta virus infection in patients with hepatitis B in the United States: An analysis of the All-Payer Claims Database
Background and Aims: Hepatitis delta virus (HDV) leads to the most severe form of viral hepatitis; however, the prevalence of HDV is not well understood. Using real-world data from the All-Payer Claims Database (APCD), this study estimates the prevalence of HBV/HDV infection among the chronic hepatitis B (HBV) population and describes patient/clinical characteristics for adults with HBV/HDV infection in the United States (US). Approach and Results: Adults (≥ 18 y) with ≥1 inpatient claim or ≥2 outpatient claims for HDV infection or HBV in the APCD from 1/1/2014 to 12/31/2020 were identified. HDV prevalence was calculated as the proportion of patients with HBV/HDV infection among total patients with HBV infection. Patient characteristics, socioeconomic status, advanced liver complications (e.g., cirrhosis, hepatocellular carcinoma), and comorbidities were assessed. A total of 6,719 -patients were diagnosed with HBV/HDV among 144,975 with HBV and 12-months of continuous data, for a prevalence of 4.6%. At diagnosis, 31.7% of patients with HBV/HDV had advanced liver complications, including compensated cirrhosis (16.3%) and decompensated cirrhosis (10.4%). Diabetes (50.5%), hypertension (49.8%), HIV infection (30.9%), were the top three comorbidities. Conclusion: In a large database capturing approximately 80% of the US insured population, HBV/HDV infection prevalence was 4.6% among HBV-infected adults. HDV-infected patients had high rates of baseline liver complications and other comorbidities at time of diagnosis, suggesting potentially delayed diagnosis and/or treatment. Earlier identification of HBV/HDV infection among the HBV population may provide opportunities to improve linkage to care and treatment, thereby reducing the risk of liver-related morbidity and mortality. Export
- Open Access
- 1 October 2023
- Published by Wolters Kluwer Health in ACG Case Reports Journal
- Vol. 10 (10) , e01151
Colonic Mass After NSAID Use and Concerns for Malignancy
- 1 October 2023
- Published by Wolters Kluwer Health in ACG Case Reports Journal
- Vol. 10 (10) , e01151
Open AccessColonic Mass After NSAID Use and Concerns for Malignancy
- Open Access
- 10 August 2023
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 68 (10) , 4062-4063
Correction to: Diagnosis and Management of Hepatitis Delta Virus Infection
- 10 August 2023
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 68 (10) , 4062-4063
Open AccessCorrection to: Diagnosis and Management of Hepatitis Delta Virus Infection